Form 4: Akero Therapeutics CSO Timothy Rolph Executes Pre-Planned Option Exercises and Share Sales

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, executed a series of pre-planned option exercises and subsequent share sales totaling approximately $2.05 million in early June 2025.

Summary

• Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), engaged in multiple transactions involving the company's common stock on June 5 and June 6, 2025.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.
• On June 5, 2025, Mr. Rolph acquired 12,500 shares of common stock through the exercise of stock options at an exercise price of $21.1 per share.
• Following the option exercise on June 5, 2025, Mr. Rolph sold a total of 12,500 shares of common stock in two separate transactions: 9,350 shares at a weighted-average price of $53.373 (ranging from $52.69 to $53.67) and 3,150 shares at a weighted-average price of $53.84 (ranging from $53.70 to $54.12).
• On June 6, 2025, Mr. Rolph acquired a total of 25,000 shares of common stock through the exercise of stock options: 24,611 shares at an exercise price of $21.09 per share and 389 shares at an exercise price of $21.1 per share.
• Following the option exercises on June 6, 2025, Mr. Rolph sold 25,000 shares of common stock at a weighted-average price of $55.04 (ranging from $55.00 to $55.18).
• The options exercised were vested and currently exercisable.
• After all reported transactions, Timothy Rolph's direct beneficial ownership of Akero Therapeutics common stock stands at 169,721 shares.

Sentiment

Score: 5

Explanation: The transactions represent routine insider activity under a pre-arranged trading plan (Rule 10b5-1), which typically carries a neutral sentiment as it is not indicative of new positive or negative information about the company's prospects.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the sales were scheduled in advance and not based on new, material non-public information, thereby reducing concerns about opportunistic insider selling.

Negatives

• The sale of shares by a Chief Scientific Officer, even if pre-planned, represents a reduction in direct insider ownership, which some investors might interpret as a lack of conviction, although this is mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape. It reflects individual executive compensation and liquidity management.

Stakeholder Impact

• Minimal direct impact on shareholders as the transactions were pre-planned under a Rule 10b5-1 trading plan, which aims to mitigate concerns about opportunistic insider trading. The net effect on outstanding shares is neutral as exercised options were immediately sold.

Key Dates

Keywords

Akero Therapeutics, AKRO, Timothy Rolph, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Chief Scientific Officer